Abstract:Among the acquired coagulation factor deficiencies, autoimmune coagulation factor deficiencies (AiCFD) are rare and result from autoantibody production against coagulation factors. In Japan, a nationwide survey on AiCFD has been conducted since 2009. Autoimmune factor XIII, factor VIII, von Willebrand factor, factor V, and factor X deficiencies (AiF13D, AiF8D, AiVWFD, AiF5D, and AiF10D, respectively) have been enacted as "designated intractable disease-282." The incidence of AiF8D, AiF13D, and AiF5D was 1.83, 0.044, and 0.038 per million people/year, respectively, whereas that of AiVWFD and AiF10D was not calculable owing to the small number of patients. AiF13D and AiF8D were often idiopathic, whereas AiVWFD was often associated with plasma cell neoplasms. Epistaxis was a characteristic symptom of AiVWFD, intramuscular bleeding was frequent in AiF13D and AiF8D, and subcutaneous bleeding (purpura) was frequent in AiF13D and AiF10D, although none were specific to any one disease. Differential diagnosis cannot be made based on bleeding symptoms alone; therefore, rapid and accurate testing is mandatory. Definitive diagnosis of AiCFD necessitates identifying the presence of coagulation factor "inhibitors" and/or "autoantibodies." Therefore, these tests should be performed upon unexplained severe acquired coagulation factor deficiencies. The mainstay of treatment for AiCFD was hemostatic therapy and autoantibody eradication therapy, which included the replacement of coagulation factors or "bypass" agents and administration of immunosuppressants. The rate of hemorrhagic death was high in AiF13D (13%), followed by AiF5D (7%) and Ai10D (5%); therefore, early diagnosis and optimal treatment are essential for AiCFDs. Given the unknown long-term prognosis, "intractable disease platform registries" have begun to accumulate in Japan. M.S. and T.O. conducted experimental examinations, statistical analyses, and proofread the manuscript. A.I. initiated and designed the study, extracted data, wrote, edited, and proofread the manuscript. Article published online: 12 June 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

A Case of Acquired Factor V Inhibitor During Bullous Pemphigoid Treatment

[Acquired hemophilia A complicated by dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid]

Bullous Pemphigoid Associated with Acquired Hemophilia A: A Case Report and Review of the Literature

Acquired hemophilia associated with bullous pemphigoid: a case report

Bullous pemphigoid associated with acquired hemophilia a: a rare association of autoimmune disease

Association of bullous pemphigoid with acquired hemophilia A: a case report

Acquired Factor V Deficiency Associated with CFPM Administration

Acquired Factor V Deficiency in a Patient with a Urinary Tract Infection Presenting with Haematuria Followed by Multiple Haemorrhages with an Extremely Low Level of Factor V Inhibitor: a Case Report and Review of the Literature.

Intravenous IgG Reduces Pathogenic Autoantibodies, Serum IL-6 Levels, and Disease Severity in Experimental Bullous Pemphigoid Models

Acquired Multiple Coagulation Factor Inhibitors Associated Bleeding Disorder

A case of autoimmune factor XIII deficiency due to clearance-accelerating and inhibitory anti-FXIII autoantibodies

Anti-laminin 332 antibodies in graft-versus-host disease-associated bullous pemphigoid after allogeneic peripheral blood stem cell transplantation

A Case of Bullous Pemphigoid with Significant Infiltration of CD4-Positive T Cells during Treatment with Pembrolizumab, Accompanied by Pembrolizumab-Induced Multi-Organ Dysfunction

Diagnosis and Treatment of Autoimmune Acquired Coagulation Factor Deficiencies: An Evidence-Based Review of Japanese Practice

Acquired Factor V Inhibitor with Lupus-Like Features

A Rare Case of Acquired Factor VIII Deficiency in an Elderly Male With a History of Rheumatoid Arthritis

A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy

Anti-idiotypic Antibodies against BP-IgG Prevent Type XVII Collagen Depletion

A Case of Autoimmune Hepatitis Complicated by Undiagnosed Factor VII Deficiency: A Pitfall of Coagulopathy

Acquired hemophilia A in the setting of dual anticoagulation therapy and lupus anticoagulant: a case report

[Acquired hemophilia A associated with bullous pemphigoid and multiple myeloma: a case report]